July 13, 2018Open Access

In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)

Key Points

Key points are not available for this paper at this time.

Abstract

The data presented here highlight the JAK1 selectivity of upadacinitinib and supports its use as an effective therapy for the treatment of RA with the potential for an improved benefit:risk profile.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Julie Parmentier

AbbVie (United States)

J W Voss

AbbVie (United States)

Candace Graff

AbbVie (United States)

Journals

BMC Rheumatology

SHILAP Revista de lepidopterología

Actions

Institutions

AbbVie (United States)

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study